

COMMENTARIES

Bone Metastasis Targets The Endosteal Hematopoietic Stem Cell Niche

Ryohichi Sugimura¹ and Linheng Li^{1,2}

¹*Stowers Institute for Medical Research, Kansas City, Missouri, USA*

²*Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA*

Commentary on: Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, Pienta KJ, Taichman RS. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. *J Clin Invest.* 2011 Apr 1;121(4):1298-312.

Bone is the most common site for metastasis, and is particularly the favorable site for prostate and breast cancer (1). However, the underlying cellular and molecular mechanisms remain elusive. Recent work published by Shiozawa and colleagues addresses this issue (2). While metastasized cancer cells and hematopoietic stem cells (HSCs) reside in the bone cavity, it remains largely unclear whether cancer cells compete with HSCs for the same niche during metastasis. Using a transplantation model of human prostate cancer to mice, Shiozawa *et al.* find that the endosteal HSC niche in the bone marrow is a direct target of prostate cancer dissemination. Prostate cancer cells competed with HSCs for occupancy of the HSC niche. In addition, engrafted prostate cancer cells were enriched with prostate cancer stem cells (CSCs). Also, cancer cells and HSCs shared the same mechanism to mobilize to the blood circulation. These findings suggest that the endosteal HSC niche plays a critical role in bone metastasis. Understanding the mechanism of cancer metastasis may provide important insight for therapeutic targeting that will be beneficial to cancer treatment.

The Endosteal HSC Niche

The endosteal bone surface is covered by bone-lining cells that include pre-osteoblasts and a specific type of macrophage (osteomacs) (3;4). Pre-osteoblasts are derived from mesenchymal stem cells and can differentiate into mature osteoblasts to form bone.

Recent studies of HSCs have revealed that the endosteal region is a niche that maintains quiescent HSCs and that N-cadherin-positive bone-lining pre-osteoblasts are one of the major components of this niche (5;6). Many adhesion molecules and signaling molecules have been reported to be involved in the maintenance of quiescent HSCs in the endosteal niche (7). Once HSCs are activated by extrinsic signaling, they will migrate from the endosteal niche and mobilize to the central marrow for circulation (8). Canonical Wnt signaling is one of the factors known to activate HSCs as well as to prompt bone-lining pre-osteoblasts to differentiate into mature osteoblasts (9).

Homing to the Endosteal HSC Niche

Almost all patients who die of prostate cancer have cancer metastasis to bone (10). However, it has not been clear whether cancer cells occupy the endosteal HSC niche during metastasis. In the current study

by Shiozawa *et al.* (2), the authors co-transplanted human prostate cancer cells and HSCs to NOD/SCID mice. They observed that cancer cells competed with HSCs for engraftment to the endosteal niche. Considering previous reports that CSCs facilitate metastasis (11), it is probable that disseminated cancer cells in the endosteal HSC niche largely contain CSCs. Results from immunostaining showed that labeled cancer cells and HSCs co-localized to the endosteal niche. When the endosteal niche was expanded by parathyroid hormone, dissemination of cancer cells was increased

in bone. In contrast, when the endosteal niche was reduced by the Col2.3 Δ -TK system, dissemination of cancer cells was reduced. To examine the underlying mechanism by which cancer cells home and mobilize, the authors used AMD3100, an inhibitor of CXCR4/SDF1 signaling, to mobilize HSCs from the endosteal niche. When mice were pre-treated with AMD3100 prior to transplantation of cancer cells, engraftment of cancer cells was increased, indicating that cancer cells use the same niche that HSCs use.




Fig. 1. A. Cancer stem cells (CSCs) and hematopoietic stem cells (HSCs) compete with each other to engraft to bone-lining pre-osteoblasts. CSCs express DKK1 to inhibit maturation of pre-osteoblasts to osteoblasts, which saves the quiescent stem cell niche for CSCs (featured in pink). In addition, NFATc1-mediated osteoclastogenesis leads to a breakdown of bone structure, causing the osteolytic feature of bone metastasis. Once CSCs are engrafted to the endosteal niche, they will propagate cancer cells. B. DKK1 expression is decreased and osteoblast maturation is enhanced. When CXCR4/SDF1 signaling is blocked by AMD3100 or G-CSF, cancer cells are mobilized from the endosteal niche. It is not clear whether CSCs are also mobilized from the niche.

Dickkopf-1 (DKK1) is one of the most frequently studied signaling molecules for cancer metastasis. Its expression is high in breast cancer, prostate cancer (in the early stages of metastasis), and multiple myeloma that metastasize to bone. DKK1 inhibits maturation of pre-osteoblasts via suppression of canonical Wnt signaling. It causes the breakdown of bone associated with NFATc1-mediated osteoclastogenesis. Once prostate cancer cells have disseminated to bone, DKK1 expression is decreased in cancer cells, allowing osteogenesis. The process opens more spaces for cancer cell metastasis (12) (Fig. 1A).

Dormancy at the Endosteal HSC Niche

Bone-lining pre-osteoblasts in the endosteal niche maintain quiescent HSCs through adhesion and signaling (7). Recent reports have revealed that leukemic stem cells (LSCs) reside in the endosteal niche and are also kept in a quiescent state. G-CSF treatment can activate these quiescent LSCs and facilitate their elimination in combination with chemotherapy (13). Interestingly, the current study by Shiozawa and colleagues showed that CD133+CD44+ cells enriching prostate CSCs were significantly higher in bone marrow 24 hours after transplantation. This observation is consistent with previous reports that CSCs facilitate metastasis (11). In addition, CD133+CD44+ prostate CSCs were more efficient than CD133-CD44- cancer cells in blocking engraftment of co-transplanted HSCs. Intriguingly CD133+CD44+ prostate CSCs expressed lower cyclin A1 and cyclin D1 in the qRT-PCR assay, suggesting slow cell-cycling of prostate CSCs. These observations indicate that the endosteal niche is the preferred targeting site for dormant prostate CSCs.

Mobilization from the Endosteal HSC Niche

The study by Shiozawa and colleagues also revealed that prostate cancer cells residing in the endosteal niche can be mobilized by AMD3100. This indicates that cancer cells

also utilized CXCR4/SDF1 signaling for mobilization, the same molecular pathway inducing HSC mobilization. G-CSF is another reagent that mobilizes HSCs from the endosteal niche. G-CSF is known to suppress CXCR4/SDF1 signaling (14) and affect osteoblasts (15). When the researchers administered G-CSF to mice engrafted with prostate cancer cells, they observed mobilization of cancer cells in peripheral blood. It will be interesting to further test whether AMD3100 and G-CSF can mobilize CD133+CD44+ prostate CSCs from the endosteal niche (Fig. 1B).

Potential Therapeutic Utility

It is important to investigate how to target dormant CSCs in the endosteal HSC niche, as the niche may protect CSCs by keeping them from cycling. One possibility is to induce CSC mobilization by AMD3100 or G-CSF. It is also critical to further address whether mobilized CSCs are sensitive to chemotherapeutic drugs.

Conclusion

The study by Shiozawa *et al.* shows that prostate CSCs metastasize to bone and compete for the endosteal HSC niche. By seizing control of the same mechanism for HSC homing or mobilization, CSCs target and are further maintained in the endosteal niche. This finding may lead to potential new therapies for cancer cell metastasis to bone, including induction of cancer cell mobilization (*e.g.*, with AMD3100 or G-CSF) from the endosteal niche.

Acknowledgment: This work was completed to fulfill, in part, requirements for Ph.D. thesis research as a student registered with the Open University (R.S).

Conflict of Interest: None reported.

Peer Review: This article has been peer-reviewed.

References

1. Coleman RE. Clinical features of metastatic bone disease and risk of

- skeletal morbidity. *Clin Cancer Res.* 2006 Oct 15;12(20 Pt 2):6243s-9s.
2. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, Pienta MJ, Song J, Wang J, Loberg RD, Krebsbach PH, Pienta KJ, Taichman RS. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. *J Clin Invest.* 2011 Apr 1;121(4):1298-312.
 3. Raggatt LJ, Partridge NC. Cellular and molecular mechanisms of bone remodeling. *J Biol Chem.* 2010 Aug 13;285(33):25103-8.
 4. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. *J Bone Miner Res.* 2001 Sep;16(9):1575-82.
 5. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG, Ross J, Haug J, Johnson T, Feng JQ, Harris S, Wiedemann LM, Mishina Y, Li L. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature.* 2003 Oct 23;425(6960):836-41.
 6. Xie Y, Yin T, Wiegraeb W, He XC, Miller D, Stark D, Perko K, Alexander R, Schwartz J, Grindley JC, Park J, Haug JS, Wunderlich JP, Li H, Zhang S, Johnson T, Feldman RA, Li L. Detection of functional haematopoietic stem cell niche using real-time imaging. *Nature.* 2009 Jan 1;457(7225):97-101.
 7. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. *Nat Rev Immunol.* 2006 Feb;6(2):93-106.
 8. Lévesque JP, Helwani FM, Winkler IG. The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization. *Leukemia.* 2010 Dec;24(12):1979-92.
 9. Malhotra S, Kincade PW. Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. *Cell Stem Cell.* 2009 Jan 9;4(1):27-36.
 10. Coleman RE, Fogelman I, Habibollahi F, North WR, Rubens RD. Selection of patients with breast cancer for routine follow-up bone scans. *Clin Oncol (R Coll Radiol).* 1990 Nov;2(6):328-32.
 11. Wicha MS. Cancer stem cells and metastasis: lethal seeds. *Clin Cancer Res.* 2006 Oct 1;12(19):5606-7.
 12. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. *Nat Rev Cancer.* 2011 Jun;11(6):411-25.
 13. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, Sone A, Najima Y, Takagi S, Aoki Y, Wake A, Taniguchi S, Shultz LD, Ishikawa F. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. *Nat Biotechnol.* 2010 Mar;28(3):275-80.
 14. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. *Nat Immunol.* 2002 Jul;3(7):687-94.
 15. Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, Frenette PS. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell.* 2006 Jan 27;124(2):407-21.

Copyright of IBMS BoneKEy is the property of International Bone & Mineral Society (IBMS) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.